Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

133.26 -33.56 (-20.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Why Insulet (PODD) Shares Are Sliding Today
What Happened? Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) fell 20.5% in the afternoon session after the company reported strong sec... 
Via StockStory
Topics Economy
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Insulet Q2 Earnings Call Highlights ↗
Insulet (NASDAQ:PODD) reported second-quarter revenue growth of 23% on a constant-currency basis, supported by demand for its Omnipod insulin-delivery system in the U.S. and international markets,... 
Via MarketBeat
Topics Earnings
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
Insulet (NASDAQ:PODD) Shares Tumble on Reduced Full-Year Outlook Despite Q2 Earnings Beat ↗
Via Chartmill
Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum ↗
Via Chartmill
Which S&P500 stocks are gapping on Monday? ↗
Via Chartmill
Insulet Corp (NASDAQ:PODD): Strong Growth Stock Consolidating Near Resistance for a Potential Breakout ↗
Via Chartmill
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Insulet’s (NASDAQ:PODD) Q2 CY2026 Sales Top Estimates But Stock Drops
Insulin delivery company Insulet Corporation (NASDAQ:PODD) announced better-than-expected revenue in Q2 CY2026, with sales up 23.5% year on year to $801.7 mi... 
Via StockStory
INSULET CORP (NASDAQ:PODD) Fits the Affordable Growth Mold with Strong Momentum and Reasonable Valuation ↗
Via Chartmill
News headline image
Insulet (PODD) Reports Earnings Tomorrow: What To Expect
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what you need to know. Insulet beat anal... 
Via StockStory
News headline image
1 Healthcare Stock to Target This Week and 2 We Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as... 
Via StockStory
News headline image
3 Quality Compounders on Our Buy List
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that genera... 
Via StockStory
News headline image
Patient Monitoring Stocks Q1 Earnings Review: Insulet (NASDAQ:PODD) Shines
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Avoid
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
1 Mid-Cap Stock Worth Your Attention and 2 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
2 S&P 500 Stocks to Target This Week and 1 That Underwhelm
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
Top S&P500 movers in Tuesday's session ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
Which S&P500 stocks are moving on Friday? ↗
Via Chartmill
News headline image
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? ↗
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out? 
Via The Motley Fool
News headline image
3 Reasons We’re Fans of Insulet (PODD)
Shareholders of Insulet would probably like to forget the past six months even happened. The stock dropped 54.4% and now trades at $144.10. This might have i... 
Via StockStory
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
Discover which S&P500 stocks are making waves on Thursday. ↗
Via Chartmill
Which S&P500 stocks are moving on Wednesday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.